Kota Itahashi

5PUBLICATIONS
56CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 15, 2026
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma.

|Nov 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

Ayaka Tsuge, Sho Watanabe, Akihito Kawazoe

|Oct 07, 2022
BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors.

Kota Itahashi, Takuma Irie, Junichiro Yuda

|Nov 12, 2021
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.

Yoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato

|Oct 01, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).

Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto

Pageof 1

Frequent Collaborators

5 joint publications

Hiroyoshi Nishikawa

4 joint publications

Shohei Koyama

2 joint publications

Sho Watanabe

2 joint publications

Daisuke Sugiyama